NaV1.8 Solid Dispersion Tablets for Neuropathic Pain Relief
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current pain therapies, particularly for neuropathic pain, suffer from poor efficacy and high adverse event risks, with limited treatment options and significant side effects, necessitating a need for analgesics with improved safety and efficacy profiles targeting specific pathophysiology mechanisms.
Innovation Solution
Development of a compound, (2R,3S,4S,5R)-4-[[3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl) tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide, which selectively inhibits voltage-gated sodium channel NaV1.8 to address pain signaling, formulated as a solid dispersion with polymers and other pharmaceutical components for effective pain management.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If lidocaine is administered at dose levels required for pain relief, then pain reduction is achieved, but side effects become prominent
Solution Approach 1:
The patent applies local quality by developing a sodium channel blocker with selective affinity for the NaV1.8 isoform, which is specifically expressed in peripheral sensory neurons involved in pain signaling. This selectivity allows the compound to target pain pathways locally while sparing other sodium channel isoforms in cardiac and skeletal muscle, thereby achieving effective pain relief with reduced systemic side effects
Solution Approach 2:
The patent segments the sodium channel target into specific isoforms (NaV1.8) rather than blocking all sodium channels non-selectively. By focusing inhibition on the pain-relevant NaV1.8 subtype while leaving other isoforms unaffected, the compound achieves differentiated action that provides analgesia without the broad side effect profile of non-selective sodium channel blockers
2Reliability
If opioid pain medications are used, then pain relief is achieved, but abuse liability and overdose risk increase
Solution Approach 1:
The patent extracts the pain-relief function from the opioid mechanism by targeting sodium channels instead of opioid receptors. This extraction removes the compound from the opioid class entirely, eliminating abuse liability and overdose risk while preserving the essential function of pain relief through an alternative mechanism of action
Solution Approach 2:
The patent uses sodium channel blockade as an intermediary mechanism to achieve pain relief without directly activating opioid receptors. By mediating analgesia through sodium channel inhibition in peripheral neurons rather than central opioid receptor activation, the compound achieves pain relief while avoiding the harmful effects associated with opioid binding
3Reliability
If antidepressants and anticonvulsants are used for neuropathic pain, then pain relief is achieved, but side effects and inadequate relief persist
Solution Approach 1:
The patent copies the successful clinical application of sodium channel blockers like lidocaine for pain relief but creates a new compound with improved properties. By developing a selective NaV1.8 blocker that mimics the analgesic mechanism of existing sodium channel blockers while adding isoform selectivity, the patent reproduces the benefits of sodium channel inhibition while eliminating the limitations of non-selective agents and off-target effects of antidepressants/anticonvulsants
4Reliability
If non-selective sodium channel blockers are used, then pain relief is achieved, but side effects in cardiac and skeletal muscle occur
Solution Approach 1:
The patent applies local quality by developing a sodium channel blocker with selective affinity for the NaV1.8 isoform, which is specifically expressed in peripheral sensory neurons involved in pain signaling. This selectivity allows the compound to target pain pathways locally while sparing other sodium channel isoforms in cardiac and skeletal muscle, thereby achieving effective pain relief with reduced systemic side effects
Solution Approach 2:
The patent segments the sodium channel target into specific isoforms (NaV1.8) rather than blocking all sodium channels non-selectively. By focusing inhibition on the pain-relevant NaV1.8 subtype while leaving other isoforms unaffected, the compound achieves differentiated action that provides analgesia without the broad side effect profile of non-selective sodium channel blockers
Data Source
Figure 1~2
Figure 3~4
Figure 5~6
AI summary
Provided is a solid dispersion of (2R,3S,4S,5R)-4-[[3-(3,4-difluoro-2-methoxy-phenyl)-4,5-dimethyl-5-(trifluoromethyl) tetrahydrofuran-2-carbonyl]amino]pyridine-2-carboxamide (Compound 1), defined as described herein, or a pharmaceutically acceptable salt thereof and a tablet containing the solid dispersion for treating pain. Also disclosed herein is Compound 1 or a pharmaceutically acceptable salt thereof for use in a method of treating pain.